{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:17:37Z","timestamp":1791901057585,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effects of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A 24\u2010week, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010arm, proof\u2010of\u2010concept study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Five centers in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Community\u2010dwelling adults (N\u00a0=\u00a040) aged 65 and older with gait speed between 0.4 and 1.0\u00a0m\/s over 4\u00a0m and an appendicular skeletal muscle index of 7.25\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or less for men and 5.67\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or less for women.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Intravenous bimagrumab 30\u00a0mg\/kg (n\u00a0=\u00a019) or placebo (n\u00a0=\u00a021).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Change from baseline in thigh muscle volume (TMV), subcutaneous and intermuscular fat, appendicular and total lean body mass, grip strength, gait speed, and 6\u2010minute walk distance (6MWD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010two (80%) participants completed the study. TMV increased by Week 2, was sustained throughout the treatment period, and remained above baseline at the end of study in bimagrumab\u2010treated participants, whereas there was no change with placebo treatment (Week 2: 5.15\u00a0\u00b1\u00a02.19% vs \u22120.34\u00a0\u00b1\u00a02.59%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001; Week 4: 6.12\u00a0\u00b1\u00a02.56% vs 0.16\u00a0\u00b1\u00a03.42%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001; Week 8: 8.01\u00a0\u00b1\u00a03.70% vs 0.35\u00a0\u00b1\u00a03.32%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001; Week 16: 7.72\u00a0\u00b1\u00a05.31% vs 0.42\u00a0\u00b1\u00a05.14%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001; Week 24: 4.80\u00a0\u00b1\u00a05.81% vs \u22121.01\u00a0\u00b1\u00a04.43%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.002). Participants with slower walking speed at baseline receiving bimagrumab had clinically meaningful and statistically significantly greater improvements in gait speed (mean 0.15\u00a0m\/s,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.009) and 6MWD (mean 82\u00a0m,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.022) than those receiving placebo at Week 16. Adverse events in the bimagrumab group included muscle\u2010related symptoms, acne, and diarrhea, most of which were mild in severity and resolved by the end of study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with bimagrumab over 16\u00a0weeks increased muscle mass and strength in older adults with sarcopenia and improved mobility in those with slow walking speed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.14927","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T02:08:42Z","timestamp":1498529322000},"page":"1988-1995","source":"Crossref","is-referenced-by-count":238,"title":["Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof\u2010of\u2010Concept Study"],"prefix":"10.1111","volume":"65","author":[{"given":"Daniel","family":"Rooks","sequence":"first","affiliation":[{"name":"Novartis Institutes for Biomedical Research Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Hariry","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Laurent","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Petricoul","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Perry","sequence":"additional","affiliation":[{"name":"Elite Research Institute Miami Lakes Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Lach\u2010Trifilieff","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronenn","family":"Roubenoff","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glu010"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5616"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406233302501"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01307-13"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001070"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2011.01.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afq034"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.21699"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1385\/JCD:6:2:75"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm095"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2006.00701.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.2.387"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12205"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1923"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00298-3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-245894"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00150314"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.14927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:18:01Z","timestamp":1762186681000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.14927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/jgs.14927"],"URL":"https:\/\/doi.org\/10.1111\/jgs.14927","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}